Role of the newer fluoroquinolones against penicillin-resistant Streptococcus pneumoniae

Infectious Diseases in Clinical Practice

Volumn 8, Issue 8, 1999, Pages 374-382

  Appelbaum, Peter C ^a   Klepser, Michael E ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; ERYTHROMYCIN; GATIFLOXACIN; GLYCOPEPTIDE; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN; WARFARIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; DRUG EFFECT; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; NONHUMAN; PENICILLIN RESISTANCE; PHOTOSENSITIVITY DISORDER; SHORT SURVEY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0032753496     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199911000-00007     Document Type: Short Survey

References (66)

1. Eriksen KR. Studies of induced resistance to penicillin in a pneumococcus type I. Acta Pathol Microbiol Scand 1945;22:398-405.
2. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967;2:264-5.
3. Kislak JW, Razavi LMB, et al. Susceptibility of pneumococci to nine antibiotics. Am J Med Sci 1965;250:261-8.
4. Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977:995-7.
5. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40.
6. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
7. Spika JS, Facklam BD, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991;163:1273-8.
8. Thornsberry C, Brown SD, Yee C, et al. Increasing penicillin resistance in Streptococcus pneumoniae in the U.S. Infect Med 1993;93:15-24.
9. Barry AL, Pfaller MA, Fuchs PC, et al. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
10. Doern GV, Brueggeman A, Holley HP Jr, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
11. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season: the TRUST Study. Diagn Microbiol Infect Dis 1997; 29:249-57.
12. Jones RN, Ballow CH, Schentag JJ, et al. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis 1998;31:313-25.
13. Thornsberry, C, Hickey ML, Diakun DR, et al. International surveillance of resistance among respiratory pathogens [abstract E-23] In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 174.
14. Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28:581-6.
15. Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1986;18:407-13.
16. Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol 1986;5:226-31.
17. Pérez-Trallero E, Garcia-Arenzana JM, Jimenez JA, et al. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumoniae treated with ciprofloxacin. Eur J Clin Microhiol Infect Dis 1990;9:905-6.
18. Kimbrough RC, Gerecht WB, Husted FC, et al. The failure of ciprofloxacin to prevent the progression of Streptococcus pneumoniae infections to meningitis. Mo Med 1991;88:635-7.
19. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990;89:383-4.
20. Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy [comment]. Am J Med 1990;88:548.
21. Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia [comment]. Am J Med 1989;87:475.
22. Hickey ML, Thornsherry C, Diakun DR, et al. Activity of ciprofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis: has it changed in the last decade [abstract E-20]? In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; Sar Diego, CA. American Society for Microbiology; 1998. p. 172.
23. Garcia-Bustos J, Tomasz A. A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. Proc Natl Acad Sci USA 1990;87:5415-9.
24. Laible G, Spratt BG, Hakenbeck R. Interspecies recombinational events during the evolution of altered PBP 2X genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Mol Microbiol 1991;5:1993-2002.
25. Dowson CG, Hutchison A, Brannigan JA, et al. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Proc Natl Acad Sci U S A 1989;86:8842-6.
26. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-82.
27. Barry AL, Fuchs PC, Allen SD, et al. In-vitro susceptibility of Streptococcus pneumoniae to d- and l-isomers of ofloxacin: interpretive criteria and quality control limits. J Antimicrob Chemother 1996;37:365-9.
28. Janior C, Zeller V, Kitzis MD, et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996;41:2760-4.
29. Lafredo SC, Foleno BD, Fu KP. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy 1993;39:36-9.
30. Varon E, Janoir C, Kitzis M-D, et al. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:302-6.
31. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997;41:471-4.
32. Klugman KP, Capper T, Bryskier A. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996;40:2802-4.
33. Tankovic J, Perichon B, Duval J, et al. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 1996;40:2505-10.
34. Kitzis MD, Gutmann L, Acar JF, et al. Selection of one step-resistant mutants Streptococcus pneumoniae with moxifloxacin with comparison to other fluoroquinolones [abstract E-208]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 229.
35. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 1996;40:2691-7.
36. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2032-5.
37. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995;99(6B Suppl):3S-7S.
38. Hoban DJ, Jones RN, Harrell LJ, et al. The North American component (the United States and Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Diagn Microbiol Infect Dis 1993;17:157-61.
39. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40: 839-45.
40. Spangler SK, Jacobs MR, Appelbaum PC. MIC and time-kill studies of antipneumococcal activity of GV 118819X (Sanfetrinem) compared with those of other agents. Antimicrob Agents Chemother 1997;41:148-55.
41. Visalli MA, Jacobs MR, Appelbaum PC. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996;40:362-6.
42. Zhanel G, Laing N, Karlowsky J, Hoban D. In vitro characterization of moxifloxacin and comparator fluoroquinolone (FQ)-induced killing of multiple drug-resistant Streptococcus pneumoniae by simulating clinically achievable areas under the curve (AUC) [abstract A-24]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 8.
43. Klugman KP, Gootz TD. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1997;39(Suppl B):51-5.
44. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-60.
45. Marchbanks CR, McKiel JR, Gilbert DH, et al. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother 1993;37:1756-63.
46. Kang SL, Rybak MJ, McGrath BJ, et al. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994;38:2702-9.
47. Palmer SM, Rybak MJ. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 1996;40:701-5.
48. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998;27:33-9.
49. Licata L, Smith CE, Goldschmidt RM, et al. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:950-5.
50. Brueggemann AB, Dickson EW, Doern GV. Comparison of the efficacy of levofloxacin, ofloxacin, and ciprofloxacin in a murine model of pneumococcal lung infection [abstract A28]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, Canada. Washington, D.C.: American Society for Microbiology; 1997. p. 6.
51. Kiesel N, Geweniger KH, Koletzki P, et al. Chemotherapeutic activity of levofloxacin (HR 355, Dr.-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother 1995;35:805-19.
52. Drain R, Lamb L, Medina I, et al. Gatifloxacin: efficacy against penicillin-resistant Streptococcus pneumoniae in an experimental murine lung infection model [abstract B-46]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 57.
53. Bedos JP, Rieux V, Bauchet J, et al. Efficacy of trova-floxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1998;42: 862-7.
54. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
55. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
56. File TM, Segreti J Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
57. Fogarty CM, Sullivan JF, Chattman MS, et al. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998;7:400-7.
58. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-38.
59. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352-64.
60. Spangler SK, Jacobs MR, Pankuch GA, et al. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424, and RP 67829. J Antimicrob Chemother 1993;31:273-80.
61. Hoellmann DB, Jacobs MR, Appelbaum PC. Antipneumococcal activity of gatifloxacin compared with eight other compounds by agar dilution [abstract E-175]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 220.
62. Esposito S, Noviello S, Ianniello F, et al. Activity of moxifloxacin and 12 other antimicrobials against 216 Streptococcus pneumoniae isolates [abstract E-199]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, CA. American Society for Microbiology; 1998. p. 226.
63. Child J, Andrews J, Boswell F, et al. The in-vitro activity of CP 99,219, a new napthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Agents 1995;35:869-76.
64. Neu HC, Chin N. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994;38:2615-22.
65. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-napthyridone. Antimicrob Agents Chemother 1993;37:349-53.
66. Eliopoulos G, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother 1993;37:366-70.